Anti-Rituximab Antibody产品信息
抗体来源(Source)
Anti-Rituximab Antibody (RIB-Y35c) are expressed from human 293 cells (HEK293).
亚型(Isotype)
Mouse IgG1/kappa
特异性(Specificity)
Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.
应用(Application)
This antibody can be paired with other CD20 antibodies to detect CD20 in sandwich ELISA or LFA assay.
纯度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
Anti-Rituximab Antibody背景
Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids, Anti-Rituximab Antibodies (RIB-Y35c) is the monoclonal antibody of Rituximab expressed with human HEK293 cells.
关键字: Rituximab;抗Rituximab抗体;Rituximab抗体;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。